Pharmaceutical Industry Jostle for Takeover Deals
The pharmaceutical industry is going through a lot of buzz as a number of companies are engaged in talks for acquisition and making deals. Some of the bigger players are busy trying to out-power their competitors.
The spell of activities in this regard remains strong in spite of the efforts that are being put in by the Obama administration to restrain the inversion or the tax-avoiding deals. There have been many deals of inversion in the health care sector this year. Talks are working out quickly and in case one falls apart other are soon in line.
The company which is the maker of Botox itself is a target of acquisition, but still Allergan is making an effort to acquire Salix Pharmaceuticals in what is a likely all-cash deal. Such kind of move will probably make the pharmaceutical company too large big for acquiring by suitors like Valeant Pharmaceuticals and Pershing Square Capital Management that are chasing Allergan with a $53 billion takeover deal.
However talks have stalled between Allergan and Salix. The entire list of the reasons for this is not known, but it seems that these two companies are unlikely to come finalize any deal.
This means that the chances of Valeant and Pershing Square is likely to prevail at a special meeting organised for Allergan shareholders on December 18, when the companies expect to vote out a majority of the board of Allergan and clear its path for a takeover.
Famed microbiologist Dr. Mark Wainberg, who played...Read More
Microsoft Corp. has claimed that it has already...Read More
Struggling to fight back soaring heroin and HIV...Read More
During the most recent Nintendo Direct, the mobile...Read More
Fresh Express is recalling a limited number of...Read More
Tech giant Google Inc. has plans to introduce a...Read More